Opinion|Videos|July 29, 2024
Overview of TROP2 & Potential Role of TROP2-Directed ADCs in NSCLC
Advertisement
Episodes in this series
- Please discuss the significance of TROP2 in the development and progression of NSCLC and the role of TROP2-directed ADCs in this treatment setting.
a. How is TROP2 unique as a biomarker in NSCLC?
b. In what ways does it differ from other targetable biomarkers in NSCLC?
c. What is the rationale for TROP2-directed therapies in previously treated
NSCLC?
Advertisement
Related to this article
Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.
Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.
Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.
Advertisement
Advertisement
Trending on OncLive
1
Stay Ahead of ESMO 2026: See What Lung Cancer Experts Are Prioritizing
2
CHMP Recommends Approval of Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer
3
VOLGA, DASL-HiCaP Data Highlight Key Genitourinary Cancer Presentations Arriving at ESMO 2026
4
Lifileucel Linked to Low Rates of Post-Discharge Severe TRAEs, Readmissions in Advanced Melanoma
5